Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
The cyclin-dependent kinase inhibitor p16 is a candidate tumour-suppressor protein that maps to a genomic locus strongly associated with familial melanoma and other tumour types. Screening of primary tumours and linkage analysis of familial melanoma pedigrees have identified many potential mutations in p16, but the functional significance of these sequence variants has remained unclear. We report here that p16 can act as a potent and specific inhibitor of progression through the G1 phase of the cell cycle, and we demonstrate that several tumour-derived alleles of p16 encode functionally compromised proteins. The ability of p16 to arrest cell-cycle progression generally correlates with inhibition of cyclin D1/Cdk4 kinase activity in vitro, with two exceptions among the alleles tested. In vivo, the presence of functional retinoblastoma protein appears to be necessary but may not be sufficient to confer full sensitivity to p16-mediated growth arrest. Our results provide support for the notion that p16 is an important cell-cycle regulator whose inactivation contributes to the outgrowth of human tumours.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, cells lacking functional RB were resistant to p16INK4a-mediated cell cycle arrest, implying that the ability of CDK4 (and later, CDK6) to drive G1 phase progression required RB (33-35) and predicting that chemical CDK4/6 inhibitors would show efficacy only if RB were functionally intact.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [35]
Citations
Cites
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
G1 phase progression: Cycling on cue
Sherr, C. J. (1994) · Cell · doi:10.1016/0092-8674(94)90540-1 · Cited by 2,674
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Effects of an Rb mutation in the mouse
Jacks, T., Fazeli, A., Schmitt, E. M., Bronson, R. T., Goodell, M. A., & Weinberg, R. A. (1992) · Nature · doi:10.1038/359295a0 · Cited by 1,755
Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53
Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V., & Vogelstein, B. (1990) · Science · doi:10.1126/science.2144057 · Cited by 1,754
(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264
Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J., & Kern, S. E. (1994) · Nature Genetics · doi:10.1038/ng0994-27 · Cited by 1,136
Distinct Roles for Cyclin-Dependent Kinases in Cell Cycle Control
van den Heuvel, S., & Harlow, E. (1993) · Science · doi:10.1126/science.8266103 · Cited by 1,092
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins
Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010
Research works printed but not linked: 2
- Mori, T. et al. Canc. Res. 54, 3396–3397 (1994).
- Otterson, G. A., Kratzke, R. A., Coxon, A., Kim, Y. W. & Kaye, F. J. Oncogene 9, 3375–3378 (1994).
Cited by
Items 101–200 of 513
Fåhraeus, R., Paramio, J. M., Ball, K. L., Laín, S., & Lane, D. P. (1996) · Current Biology · doi:10.1016/s0960-9822(02)00425-6 · Cited by 170
Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization
Arendt, T. (2001) · Neuroscience · doi:10.1016/s0306-4522(00)00516-9 · Cited by 169
Non-canonical functions of the RB protein in cancer
Dick, F. A., Goodrich, D. W., Sage, J., & Dyson, N. J. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0008-5 · Cited by 168
Inoue, K., & Sherr, C. J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.3.1590 · Cited by 168
p16 INK4A Participates in a G 1 Arrest Checkpoint in Response to DNA Damage
Shapiro, G. I., Edwards, C. D., Ewen, M. E., & Rollins, B. J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.378 · Cited by 165
Byeon, I.-J. L., Li, J., Ericson, K., Selby, T. L., Tevelev, A., Kim, H.-J., O'Maille, P., & Tsai, M.-D. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80042-8 · Cited by 163
Melanoma genetics: An update with focus on the CDKN2A(p16)/ARF tumor suppressors
Piepkorn, M. (2000) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2000.104687 · Cited by 162
Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues
Pei, X.-H., & Xiong, Y. (2005) · Oncogene · doi:10.1038/sj.onc.1208611 · Cited by 158
“…1997; McConnell et al., 1999; Mitra et al., 1999). p16-imposed cell cycle arrest can be reversed by the overexpression of catalytically inactive CDK4 (Koh et al., 1995; Jiang et al., 1998), suggesting that the catalytic function of CDK4 is not essential, and titration of p21 away from CDK2 could…”
BackgroundUnrestricted cell cycling and cancer
Strauss, M., Lukas, J., & Bartek, J. (1995) · Nature Medicine · doi:10.1038/nm1295-1245 · Cited by 158
Ansari-Lari, M. A., Staebler, A., Zaino, R. J., Shah, K. V., & Ronnett, B. M. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200402000-00002 · Cited by 158
Kaye, F. J. (2002) · Oncogene · doi:10.1038/sj.onc.1205834 · Cited by 153
“While this prediction was soon confirmed (Koh et al., 1995), the model of p16 as an exclusive regulator of activated cyclin D may be vastly oversimplified.”
ResultPlatz, A., Hansson, J., Mansson-Brahme, E., Lagerlof, B., Linder, S., Ringborg, U., Lundqvist, E., Sevigny, P., & Inganas, M. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.10.697 · Cited by 154
p16INK4a can initiate an autonomous senescence program
Dai, C. Y., & Enders, G. H. (2000) · Oncogene · doi:10.1038/sj.onc.1203438 · Cited by 169
Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control
Oelgeschläger, T. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10058 · Cited by 169
Zhang, S., Ramsay, E. S., & Mock, B. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2429 · Cited by 147
Requirements for Cell Cycle Arrest by p16INK4a
Bruce, J. L., Hurford, R. K., Classon, M., Koh, J., & Dyson, N. J. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00072-1 · Cited by 157
The INK4 Family of CDK Inhibitors
Carnero, A., & Hannon, G. J. (1998) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-71941-7_3 · Cited by 189
Sano, T., Oyama, T., Kashiwabara, K., Fukuda, T., & Nakajima, T. (1998) · Pathology International · doi:10.1111/j.1440-1827.1998.tb03954.x · Cited by 141
p19 Arf induces p53-dependent apoptosis during Abelson virus-mediated pre-B cell transformation
Radfar, A., Unnikrishnan, I., Lee, H.-W., DePinho, R. A., & Rosenberg, N. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13194 · Cited by 138
Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma.
Flores, J. F., Walker, G. J., Glendening, J. M., Haluska, F. G., Castresana, J. S., Rubio, M., Pastorfide, G. C., Boyer, L. A., Kao, W. H., Bulyk, M. L., et al. (1996) · PubMed · Cited by 169
Human T-cell leukemia virus type 1 Tax releases cell cycle arrest induced by p16INK4a
Low, K. G., Dorner, L. F., Fernando, D. B., Grossman, J., Jeang, K. T., & Comb, M. J. (1997) · Journal of Virology · doi:10.1128/jvi.71.3.1956-1962.1997 · Cited by 132
Chan, P. A., Duraisamy, S., Miller, P. J., Newell, J. A., McBride, C., Bond, J. P., Raevaara, T., Ollila, S., Nyström, M., Grimm, A. J., et al. (2007) · Human Mutation · doi:10.1002/humu.20492 · Cited by 131
Interaction of D-Type Cyclins with a Novel myb-Like Transcription Factor, DMP1
Hirai, H., & Sherr, C. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.11.6457 · Cited by 130
Franklin, D. S., & Xiong, Y. (1996) · Molecular Biology of the Cell · doi:10.1091/mbc.7.10.1587 · Cited by 128
Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.
Srethapakdi, M., Liu, F., Tavorath, R., & Rosen, N. X. (2000) · PubMed · Cited by 136
Induction of p21 WAF1/CIP1 and Inhibition of Cdk2 Mediated by the Tumor Suppressor p16 INK4a
Mitra, J., Dai, C. Y., Somasundaram, K., El-Deiry, W. S., Satyamoorthy, K., Herlyn, M., & Enders, G. H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3916 · Cited by 126
Markey, M. P., Angus, S. P., Strobeck, M. W., Williams, S., Gunawardena, R. W., Aronow, B. J., & Knudsen, E. S. (2002) · PubMed · Cited by 140
Salvesen, H. B., Das, S., & Akslen, L. A. (2000) · PubMed · Cited by 121
Stability and folding of the tumour suppressor protein p16 1 1Edited by J. Karn
Tang, K. S., Guralnick, B. J., Wang, W. K., Fersht, A. R., & Itzhaki, L. S. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.2420 · Cited by 134
Rowland, B. D., Denissov, S. G., Douma, S., Stunnenberg, H. G., Bernards, R., & Peeper, D. S. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00085-5 · Cited by 120
“…are not immortal and still undergo RASV12- or p19ARF-induced arrest, p21CIP1 likely is not a critical p19ARF/p53 target gene in(Bruce et al., 2000; Koh et al., 1995; Lukas et al., 1995; Medema et al., 1995). p19ARF, too, is a tumor suppressor gene that has this setting (Groth et al., 2000;…”
BackgroundNoda, I., Fujieda, S., Seki, M., Tanaka, N., Sunaga, H., Ohtsubo, T., Tsuzuki, H., Fan, G., & Saitô, H. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990118)80:2<279::aid-ijc18>3.0.co;2-n · Cited by 73
Hui, R., Macmillan, R. D., Kenny, F. S., Musgrove, E. A., Blamey, R. W., Nicholson, R. I., Robertson, J. F. R., & Sutherland, R. L. (2000) · PubMed · Cited by 143
Cyclin E, a redundant cyclin in breast cancer
Gray-Bablin, J., Zalvide, J. B., Fox, M., Knickerbocker, C. J., DeCaprio, J. A., & Keyomarsi, K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15215 · Cited by 129
Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines
Melnikova, V. O., Bolshakov, S. V., Walker, C., & Ananthaswamy, H. N. (2004) · Oncogene · doi:10.1038/sj.onc.1207405 · Cited by 132
Isolation and characterization of p19INK4d, a p16-related inhibitor specific to CDK6 and CDK4.
Guan, K. L., Jenkins, C. W., Li, Y., O'Keefe, C. L., Noh, S., Wu, X., Zariwala, M., Matera, A. G., & Xiong, Y. (1996) · Molecular Biology of the Cell · doi:10.1091/mbc.7.1.57 · Cited by 118
lin-35Rb andcki-1Cip/Kip cooperate in developmental regulation of G1 progression inC. elegans
Boxem, M., & van den Heuvel, S. (2001) · Development · doi:10.1242/dev.128.21.4349 · Cited by 141
Gius, D. R., Ezhevsky, S. A., Becker‐Hapak, M., Nagahara, H., Wei, M. C., & Dowdy, S. F. (1999) · PubMed · Cited by 116
Overview of high-risk HPV's 16 and 18 infected cervical cancer: Pathogenesis to prevention
Ramakrishnan, S., Partricia, S., & Ganeshan, M. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.12.041 · Cited by 115
Compensation of BRG-1 Function by Brm
Strobeck, M. W., Reisman, D. N., Gunawardena, R. W., Betz, B. L., Angus, S. P., Knudsen, K. E., Kowalik, T. F., Weissman, B. E., & Knudsen, E. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109532200 · Cited by 114
Hangaishi, A., Ogawa, S., Imamura, N., Miyawaki, S., Miura, Y., Uike, N., Shimazaki, C., Emi, N., Takeyama, K., Hirosawa, S., et al. (1996) · Blood · doi:10.1182/blood.v87.12.4949.bloodjournal87124949 · Cited by 115
Expression of INK4 inhibitors of cyclin D-dependent kinases during mouse brain development.
Zindy, F., Soares, H. D., Herzog, K., Morgan, J., Sherr, C. J., & Roussel, M. F. (1997) · PubMed · Cited by 140
DNA methylation in prostate cancer
Li, L., Okino, S. T., & Dahiya, R. (2004) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2004.06.001 · Cited by 134
A question of balance: the role of cyclin-kinase inhibitors in development and tumorigenesis
Elledge, S. J., Winston, J. T., & Harper, J. W. (1996) · Trends in Cell Biology · doi:10.1016/0962-8924(96)10030-1 · Cited by 120
Cdk6–cyclin D3 activity in murine ES cells is resistant to inhibition by p16INK4a
Faast, R., White, J., Cartwright, P., Crocker, L. A., Šarčević, B., & Dalton, S. (2004) · Oncogene · doi:10.1038/sj.onc.1207133 · Cited by 126
Requirement of Cyclin E-Cdk2 Inhibition in p16 INK4a -Mediated Growth Suppression
Jiang, H., Chou, H. S., & Zhu, L. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.9.5284 · Cited by 113
HMGIC expression in human adult and fetal tissues and in uterine leiomyomata
Gattás, G. J. F., Quade, B. J., Nowak, R. A., & Morton, C. C. (1999) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199908)25:4<384::aid-gcc11>3.0.co;2-d · Cited by 144
Cell Cycle–Targeted Cancer Therapies
Sherr, C. J., & Bártek, J. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-040716-075628 · Cited by 130
Mutations in the INK4a/ARF Melanoma Susceptibility Locus Functionally Impair p14ARF
Rizos, H., Darmanian, A., Holland, E. A., Mann, G. J., & Kefford, R. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105299200 · Cited by 123
Honma, T., Yoshizumi, T., Hashimoto, N., Hayashi, K., Kawanishi, N., Fukasawa, K., Takaki, T., Ikeura, C., Ikuta, M., Suzuki‐Takahashi, I., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010326y · Cited by 120
Sano, T., Masuda, N., Oyama, T., & Nakajima, T. (2002) · Pathology International · doi:10.1046/j.1440-1827.2002.01359.x · Cited by 117
Manne, U., Myers, R. B., Moron, C., Poczatek, R. B., Dillard, S. C., Weiss, H. L., Brown, D., Srivastava, S., & Grizzle, W. E. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970620)74:3<296::aid-ijc11>3.0.co;2-a · Cited by 163
Ostrowski, S. M., & Fisher, D. E. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.08.010 · Cited by 148
E2F4 Is Exported from the Nucleus in a CRM1-Dependent Manner
Gaubatz, S., Lees, J. A., Lindeman, G. J., & Livingston, D. M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.4.1384-1392.2001 · Cited by 106
Mælandsmo, G., Flørenes, V., Hovig, E., Øyjord, T., Engebraaten, O., Holm, R., Børresen, A.-L., & Fodstad, Ø. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.181 · Cited by 106
Assessment of functional effects of unclassified genetic variants
Couch, F. J., Rasmussen, L. J., Hofstra, R., Monteiro, A. N. A., Greenblatt, M. S., de Wind, N., & for the IARC Unclassified Genetic Variants Working Group (2008) · Human Mutation · doi:10.1002/humu.20899 · Cited by 105
Regulation of CDK4 activity by a novel CDK4-binding protein, p34SEI-1
Sugimoto, M., Nakamura, T., Ohtani, N., Hampson, L., HAMPSON, I. N., Shimamoto, A., Furuichi, Y., Okumura, K., Niwa, S., Taya, Y., et al. (1999) · Genes & Development · doi:10.1101/gad.13.22.3027 · Cited by 122
Human papillomavirus-positive tonsillar carcinomas: a different tumor entity?
Klußmann, J. P., Weissenborn, S. J., Wieland, U., Dries, V., Eckel, H. E., Pfister, H., & Fuchs, P. G. (2003) · Medical Microbiology and Immunology · doi:10.1007/s00430-002-0126-1 · Cited by 100
Role of Cyclin-Dependent Kinases and Their Inhibitors in Cellular Differentiation and Development
Chellappan, S., Giordano, A., & Fisher, P. B. (1998) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-71941-7_4 · Cited by 102
p57Kip2, a Glucocorticoid-Induced Inhibitor of Cell Cycle Progression in HeLa Cells
Samuelsson, M. K. R. (1999) · Molecular Endocrinology · doi:10.1210/me.13.11.1811 · Cited by 99
Increased histone H1 phosphorylation and relaxed chromatin structure in Rb-deficient fibroblasts.
Herrera, R. E., Chen, F., & Weinberg, R. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11510 · Cited by 98
p16 and p16 beta are potent growth suppressors of head and neck squamous carcinoma cells in vitro.
Liggett, W. H., Sewell, D. A., Rocco, J., Ahrendt, S. A., Koch, W. M., & Sidransky, D. (1996) · PubMed · Cited by 114
Emig, R., Magener, A., Ehemann, V, Meyer, A., Stilgenbauer, F., Volkmann, M., Wallwiener, D., & Sinn, H. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.739 · Cited by 97
Arresting developments in the cardiac myocyte cell cycle: Role of cyclin-dependent kinase inhibitors
Brooks, G., Poolman, R. A., & Li, J. M. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(98)00125-4 · Cited by 113
Structure of the cyclin-dependent kinase inhibitor p19Ink4d
Luh, F. Y., Archer, S. J., Domaille, P. J., Smith, B. O., Owen, D., Brotherton, D. H., Raine, A. R. C., Xu, X., Brizuela, L., Brenner, S. L., et al. (1997) · Nature · doi:10.1038/40202 · Cited by 114
Kim, K. S., Sack, J. S., Tokarski, J. S., Qian, L., Chao, S. T., Leith, L. W., Kelly, Y. F., Misra, R. N., Hunt, J. T., Kimball, S. D., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000231g · Cited by 104
Ultraviolet radiation induces p16CDKN2A expression in human skin.
Pavey, S. J., Conroy, S., Russell, T., & Gabrielli, B. G. (1999) · PubMed · Cited by 117
MOZ (MYST3, KAT6A) inhibits senescence via the INK4A-ARF pathway
Sheikh, B. N., Phipson, B., El-Saafin, F., Vanyai, H. K., Downer, N. L., Bird, M., Kueh, A. J., May, R. E., Smyth, G. K., Voss, A. K., et al. (2015) · Oncogene · doi:10.1038/onc.2015.33 · Cited by 98
Serological evidence of an association betweenChlamydia pneumoniae infection and lung cancer
Laurila, A. L., Anttila, T., Läärä, E., Bloigu, A., Virtamo, J., Albanes, D., Leinonen, M., & Saikku, P. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970220)74:1<31::aid-ijc6>3.0.co;2-1 · Cited by 138
Temperature-Sensitive Mutants of p16CDKN2 Associated with Familial Melanoma
Parry, D., & Peters, G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.7.3844 · Cited by 94
Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines
Sartor, M., Steingrimsdottir, H., Elamin, F., Gäken, J. A., Warnakulasuriya, S., Partridge, M., Thakker, N., Johnson, N. W., & Tavassoli, M. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690505 · Cited by 103
Dai, C. Y., Furth, E. E., Mick, R., Koh, J., Takayama, T., Niitsu, Y., & Enders, G. H. (2000) · Gastroenterology · doi:10.1053/gast.2000.17952 · Cited by 92
Wang, J., Lee, J. J., Wang, L., Liu, D. D., Lu, C., Fan, Y.-H., Hong, W. K., & Mao, L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0652 · Cited by 94
Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines
Park, Y.-B., Park, M. J., Kimura, K., Shimizu, K., Lee, S. H., & Yokota, J. (2002) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(01)00575-1 · Cited by 100
Hawkins, L., Johnson, L., Bauzon, M., Nye, J. A., Castro, D., Kitzes, G., Young, M., Holt, J., Trown, P. W., & Hermiston, T. M. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301507 · Cited by 91
Arendt, T. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00216-5 · Cited by 97
Schang, L. M., Hossain, A., & Jones, C. (1996) · Journal of Virology · doi:10.1128/jvi.70.6.3807-3814.1996 · Cited by 93
Fuxe, J., Akusjärvi, G., Goike, H. M., Roos, G., Collins, V. P., & Pettersson, R. F. (2000) · PubMed · Cited by 99
Kato, D., Miyazawa, K., Ruas, M., Starborg, M., Wada, I., Oka, T., Sakai, T., Peters, G., & Hara, E. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00426-8 · Cited by 87
Low Prevalence of Germline CDKN2A and CDK4 Mutations in Patients With Early-Onset Melanoma
Tsao, H., Zhang, X., Kwitkiwski, K., Finkelstein, D. M., Sober, A. J., & Haluska, F. G. (2000) · Archives of Dermatology · doi:10.1001/archderm.136.9.1118 · Cited by 87
CDKN2A (p16INK4A) somatic and germline mutations
Smith-Sørensen, B., & Hovig, E. (1996) · Human Mutation · doi:10.1002/(sici)1098-1004(1996)7:4<294::aid-humu2>3.0.co;2-9 · Cited by 87
Kelly, B. L., Wolfe, K. G., & Roberts, J. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2535 · Cited by 102
Calbó, J., Parreño, M., Sotillo, E., Yong, T., Mazo, A., Garriga, J., & Graña, X. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m209181200 · Cited by 94
Phelps, D. E., Hsiao, K.-M., Li, Y., Hu, N., Franklin, D. S., Westphal, E., Lee, E. Y.-H. P., & Xiong, Y. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.4.2334 · Cited by 86
Nitta, R. T., Jameson, S. A., Kudlow, B. A., Conlan, L. A., & Kennedy, B. K. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02464-05 · Cited by 84
Allelic deletion at chromosome 9p21(p16) and 17p13(p53) in microdissected sporadic dysplastic nevus
Park, W., Vortmeyer, A. O., Pack, S., Duray, P. H., Böni, R., Guerami, A. A., Emmert‐Buck, M. R., Liotta, L. A., & Zhuang, Z. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90221-0 · Cited by 87
Aberrations of the G1- and G1/S-regulating genes in human cancer
Bártková, J., Lukas, J., & Bártek, J. (1997) · Springer eBooks · doi:10.1007/978-1-4615-5371-7_16 · Cited by 100
Genetically engineered mouse models of melanoma
Pérez‐Guijarro, E., Day, C., Merlino, G. T., & Zaidi, M. R. (2017) · Cancer · doi:10.1002/cncr.30684 · Cited by 103
Vidal, A., Millard, S. S., Miller, J. P., & Koff, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112090200 · Cited by 83
Leone, G., DeGregori, J., Jakoi, L., Cook, J. G., & Nevins, J. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6626 · Cited by 83
Efficiency Alleles of the Pctr1 Modifier Locus for Plasmacytoma Susceptibility
Zhang, S.-L., DuBois, W., Ramsay, E. S., Bliskovski, V., Morse, H. C., Taddesse-Heath, L., Vass, W. C., DePinho, R. A., & Mock, B. A. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.1.310-318.2001 · Cited by 82
The INK4A/ARF Locus: Role in Cell Cycle Control and Apoptosis and Implications for Glioma Growth
Ivanchuk, S. M., Mondal, S., Dirks, P. B., & Rutka, J. T. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1010632309113 · Cited by 93
Restoration of retinoblastoma mediated signaling to Cdk2 results in cell cycle arrest
Strobeck, M. W., Fribourg, A. F., Puga, A., & Knudsen, E. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203510 · Cited by 88
High prevalence of p16 genetic alterations in head and neck tumours
Miracca, E. C., Kowalski, L. P., & Nagai, M. A. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690747 · Cited by 81
Developmental defects and tumor predisposition in Rb mutant mice
Vooijs, M., & Berns, A. J. M. (1999) · Oncogene · doi:10.1038/sj.onc.1202999 · Cited by 82
Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL)
Hatta, Y., & Koeffler, H. (2002) · Leukemia · doi:10.1038/sj.leu.2402458 · Cited by 90
Tsai, K. Y., & Tsao, H. (2004) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.30037 · Cited by 87
Signaling by ABL oncogenes through cyclin D1.
Afar, D. E., McLaughlin, J., Sherr, C. J., Witte, O. N., & Roussel, M. F. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.21.9540 · Cited by 78
Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects
Griewank, K., Scolyer, R. A., Thompson, J. F., Flaherty, K. T., Schadendorf, D., & Murali, R. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt435 · Cited by 87
The cyclin D1b splice variant: an old oncogene learns new tricks.
Knudsen, K. E. (2006) · Cell Division · doi:10.1186/1747-1028-1-15 · Cited by 93
Moller, H., & Skakkebæk, N. E. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960503)66:3<287::aid-ijc2>3.0.co;2-v · Cited by 192
Metadata
- Authors
- Koh, J., Enders, G. H., David Dynlacht, B., & Harlow, E.
- Affiliations
- Massachusetts General Hospital (US)
- ORCID
- Koh, James
- Venue
- Nature
- Published
- 1995-06
- Volume
- 375
- Issue
- 6531
- Pages
- 506-510
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2035882662
- Cited by
- 516
- References
- 26
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 8 · 2022: 2 · 2021: 9 · 2020: 6 · 2019: 5 · 2018: 5 · 2017: 10 · 2016: 11 · 2015: 9 · 2014: 9 · 2013: 14 · 2012: 8
- FWCI
- 25.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- p16, tumour suppressor, cyclin-dependent kinase inhibitors, G1 cell cycle arrest, retinoblastoma protein, familial melanoma, tumor progression, cell cycle regulation
- MeSH terms
- Alleles, Animals, Carrier Proteins, Cell Line, Humans, Mutation, Recombinant Proteins, Transfection, Tumor Cells, Cultured, Genes, Tumor Suppressor, G1 Phase, 3T3 Cells, Cyclin-Dependent Kinase Inhibitor p16, Protein Kinase Inhibitors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.